OncoC4, a biotechnology company focused on clinical-stage innovations, recently completed a Series B financing round at nearly $50 million. The GBA Fund led this funding round, with contributions from the company’s co-founders and existing investors, including HM Capital, 3E Bioventures Capital, and Kaitai Capital. This funding will play a significant role in advancing the company’s development agenda.
Founded in 2020, OncoC4 was established by two immunologists and serial entrepreneurs, Dr. Yang Liu and Dr. Pan Zheng. With a background in immuno-oncology and translational medicine, the founders have positioned OncoC4 to innovate within this vital field of research. Their vision has led the company to develop a diverse pipeline of therapies that aim to address significant unmet medical needs in cancer treatment.
The funding will primarily be allocated towards advancing the clinical development of OncoC4’s pipeline programs. This funding underscores the company’s commitment to developing innovative therapies for patients, demonstrating the confidence investors have in the company’s potential to succeed in the competitive biotechnology landscape.
KEY QUOTE:
“Our Series B financing round progressed rapidly, and we deeply appreciate our investors’ recognition of our Company and continual support. We are committed to rigorously advancing the global development of our core pipeline, while strategically expanding business development activities, with the ultimate goal of delivering more disruptive therapies to patients worldwide.”
Dr. Yang Liu, Co-Founder, Chairman of the Board, CEO and CSO of OncoC4
